Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 199

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 199
---
 on behalf of or in the name of, against or otherwise involving Enfusion, the Enfusion Board, any committee thereof and/or any of the Enfusion’s directors or officers relating directly or indirectly to the Merger 
 Agreement, the Transactions or any related transaction prior to the Effective Time or any demand or proceeding for appraisal or the fair value of any shares of Enfusion Common Stock and Enfusion Class B Common Stock pursuant to the DGCL in 
 connection with the Merger Agreement;                                                                                                                                                                                                           |

| (I) | any outbreak, continuation or escalation of acts of terrorism, hostilities, sabotage or war (whether or not                                                                                                                                                                                                                                                                                                                   
 declared, including the Russian-Ukrainian and Israeli-Palestinian conflicts, and escalations and effects thereof), hurricanes, volcanoes, tornados, floods, earthquakes, tsunamis, mudslides, weather-related events, epidemics, pandemics (including COVID-19), plagues, other outbreaks of illness or public health events, fires or natural or man-made disaster or act of God, including any worsening of such conditions 
 existing as of the date of the Merger Agreement; or                                                                                                                                                                                                                                                                                                                                                                           |

| (J) | any failure by Enfusion to meet, or changes to, internal or analysts’ estimates, projections,                                                                                                                                                      
 expectations, budgets or forecasts of operating statistics, revenue, earnings, cash flow or any other financial or performance measures (whether made by Enfusion or any third parties), any change in Enfusion’s credit ratings, or any change in 
 the price or trading volume of shares of Enfusion Common Stock (the underlying causes of such failures or changes in this clause (J) may be taken into account in determining whether a Enfusion Material Adverse Effect has occurred, unless such 
 underlying cause would otherwise be excepted by this definition);                                                                                                                                                                                  |

providedthat in the case of clauses (C), (D), (E), (F) and (I), any Effect may be taken into account in determining whether or not there has been a Enfusion Material Adverse Effect, but only to the extent such Effect has had or would reasonably be expected to have, individually or in the aggregate, a disproportionate adverse effect on Enfusion and its subsidiaries, taken as a whole, as compared to other similarly situated participants in the industry in which Enfusion and its subsidiaries operate, in which case only the incremental disproportionate impact or impacts may be taken into account in determining whether or not there has been a Enfusion Material Adverse Effect. “ Clearwater Material Ad